healthcare_innovation

Jacksonville, Fla. – September 13, 2026 -- Alan Alwakeel, a recent graduate of Stanton College Preparatory School, received a $3,000 Humane Science Award from the National Anti-Vivisection Society (NAVS) for an AI-powered cancer therapy simulation platform that eliminates the need for animal testing.

Platform simulates cancer treatment efficacy without animal trials

Alwakeel's project, "The Virtual Cell 2.0: Expanding Precision and Personalized Cancer Therapy Through AI-Powered Simulation," applies computational frameworks to evaluate potential cancer treatment outcomes. The tool aims to accelerate how new therapies are developed, tested and deployed by replacing traditional animal-based testing methods with data-driven simulation.

Austin, Texas – September 11, 2026 -- Humann, the Austin-based cardiovascular supplement maker behind SuperBeets, has formed a research partnership with the University of California, Davis and appointed Dr. Harold Schmitz, Ph.D., as Chair of its Science Advisory Board to lead the collaboration.

Schmitz brings Mars Inc. science leadership to cardiovascular nutrition research

Dr. Schmitz previously served as Chief Science Officer at Mars, Inc. and as Senior Scholar at the UC Davis Graduate School of Management, with a background in nitric oxide research and food and nutrition innovation. In his new role, he will direct the partnership with UC Davis' Innovation Institute for Food and Health (IIFH), which will design and run scientific studies, including clinical trials, examining how nutrition influences cardiovascular health across life stages in women and men.

Salt Lake City – September 11, 2026 -- A decade-long study by ARUP Laboratories found that 50% of pregnancies with atypical prenatal cell-free DNA (cfDNA) screening results carried at least one clinically significant abnormality confirmed by follow-up testing, reshaping how providers should respond to inconclusive genetic screens.

ARUP analyzed over 200 atypical cfDNA cases spanning more than 10 years

Researchers reviewed more than 10 years of data and over 200 cases where atypical cfDNA screening results were followed by additional prenatal, postnatal, or maternal testing. The findings, published in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG), represent what ARUP describes as the largest study of its kind on atypical cfDNA findings.

Laval – September 11, 2026 -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and Belgian biotech YUN have expanded their strategic partnership to Mexico and additional EMEA markets, building on a 2025 launch in Poland.

Partnership adds five new markets across EMEA and Latin America

The collaboration has extended YUN's acne-prone and eczema-prone skincare lines into the Czech Republic, Slovakia, Ukraine and Bulgaria, alongside a fresh entry into Mexico. A further rollout in Kazakhstan is expected in October 2026.

Poland launch deepens into eczema care after 2025 acne debut

In Poland, Bausch Health broadened its dermatology portfolio with YUN's eczema-focused skincare, following last year's introduction of the company's probiotic-based acne-prone skin products.

Jupiter, Fla. – September 09, 2026 -- Bloomberg Television will broadcast a new episode of Advancements with Ted Danson on Saturday, September 12 at 8:00 p.m. ET, profiling four technology sectors ranging from targeted cancer therapy to space-based solar reflection. The episode features Lila Biologics, Reflect Orbital, Primary Packaging Resources, and Taica North America across separate segments.

AI-designed molecular binders aim to improve radioligand cancer therapy targeting

The episode examines radiopharmaceuticals and targeted radioligand therapy (RLT), where engineered molecules deliver radiation directly to tumors while sparing healthy tissue. Lila Biologics is featured discussing computationally designed mini binders intended to improve tumor targeting, stability, manufacturability, and therapeutic performance for cancer treatments.

San Antonio – September 09, 2026 -- Frost & Sullivan has named Amwell the recipient of its 2026 United States Technology Innovation Leadership Recognition in the Technology-Enabled Care Platforms industry, citing the company's unified platform for connecting patients, health plan members, clinicians and partner networks.

Amwell platform now supports 90 million covered lives and 38.7 million virtual visits

Frost & Sullivan's benchmarking evaluated Amwell across strategy effectiveness and strategy execution, awarding top marks in both categories. The firm pointed to the platform's clinically integrated workflows and scalability as differentiators for organizations seeking to consolidate fragmented point solutions into a single operating layer spanning virtual primary care, urgent care, behavioral health and chronic condition management.

Rotterdam – September 08, 2026 -- United Imaging has secured CE Mark certification for the uCT SiriuX and uCT SiriuX Ultrix, clearing what the company calls the world's first dual wide-coverage computed tomography family for commercial sale across Europe.

CE Mark Clears Twin-Ring Gantry System for European Sale

The certification covers a platform built on a Twin-Ring Gantry architecture, integrating dual-wide 16 cm Ultrix detectors with two liquid-metal-bearing X-ray tubes. The approval allows United Imaging to bring the systems into clinical use throughout the European market.

Melbourne, Australia – September 07, 2026 -- Helfie AI has appointed John Rego as Chief Financial Officer, bringing a track record of raising more than $10 billion in capital and closing over two dozen M&A transactions across six public and private companies.

Rego joins Helfie from Wide Open West following the US broadband provider's 2026 sale

Rego served as CFO of Wide Open West (NYSE: WOW) from 2020 until the company was sold in 2026. The appointment gives Helfie AI, a Melbourne-based AI-powered preventative healthcare platform, a finance chief with direct experience managing a company through to a market exit.

New Haven, Conn. – September 04, 2026 -- Wellinks, a virtual-first cardiopulmonary care company, has appointed Andrew Agwunobi, MD, MBA, and Mike Waters to its Board of Directors while adding three vice presidents to its management team, the company said.

Former Teladoc COO Mike Waters joins Wellinks board with digital health portfolio

Waters, who spent more than two decades in strategic operations and previously served as Chief Operating Officer of Teladoc Health, also brings 15-plus years from Providence Health, where he was Executive Vice President and Chief Executive of its Ambulatory Care Network. He currently holds board roles across six digital health companies, including Chair positions at Ieso and Brook Health.